期刊文献+

显微手术外侧裂入路治疗高血压丘脑出血 被引量:7

Microsurgical treatment via lateral fissure approach for hypertensive thalamic hemorrhage
下载PDF
导出
摘要 目的观察显微手术外侧裂入路显微手术治疗高血压性丘脑出血的疗效。方法对36例高血压性丘脑出血采用经外侧裂入路小骨窗开颅或去骨瓣减压开颅,显微镜下清除血肿。结果全部病例血肿清除满意,术后24h内复查了解血肿清除情况,23例血肿清除100%,6例血肿清除90%以上,7例血肿清除80%以上。结论外侧裂入路显微手术创伤小,止血可靠,能有效降低颅内压,是治疗高血压性基底节区出血的有效手术方式之一。 Objective To study the clinical effect of microsurgery via lateral fissure treating hypertensive thalamic hemorrhage,and summarize the clinical experience. Methods Craniotomy with small bone flap via lateral fissure or/and decompressive craniectomy were applied to evacuate hematoma originating from hypertensive thalamic hemorrhage,36 cases were analyzed retrospectively. Results The effect of this method was satisfactory. Total evacuation was achieved in 23 cases(93.9%), hematoma was removed over 90% in 6 cases and over 80% in 7 cases. Conclusion Microsurgical treatment via lateral fissure approach has the advantage of minal invasion,good operational field exposure and less impairment on normal brain tissue by manipulation through normal anatomical spaces and unimportant domain. It possesses the merits of finding bleeding part quickly,performing hemostasis effectively, reducing secondary bleeding and evacuating hematoma thoroughly,and it is one of the effective methods for hypertensive thalamic hemorrhage.
出处 《中国实用神经疾病杂志》 2009年第7期28-31,共4页 Chinese Journal of Practical Nervous Diseases
基金 开封市科技发展计划项目(080342)
关键词 高血压丘脑出血 外侧裂入路 显微手术 Hypertensive thalamic hemorrhage Lateral fissure approach Microsurgery
  • 相关文献

参考文献3

二级参考文献21

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2[8]Franco V,Oparil S,Carretero OA.Hypertensivetherapy:Part I.Circulation,2004,109:2953-2958.
  • 3[9]Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in b1 prospective studies. Lancet,2002, 360:1903-1913.
  • 4[10]Vasarn RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohot study. Lancet, 2001, 358:1682-1686.
  • 5[11]Guideline Subcommittee. 1999 World Health Organization-International Society of Hypertension Guideline for the Management of Hypertension. J Hypertens, 1999, 17:151-183.
  • 6[12]European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003, 21:1011-1053.
  • 7[13]The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med, 1997, 157:2413-2446.
  • 8[14]Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359:1004-1010.
  • 9[15]Hansson L, Hendner T, eds. Hypertension Manual 1999. 2 nd ed.Sweden: Elanders Gummessons AB, 1999. 64-94.
  • 10[16]Kaplan NM. Systemic hypertension: mechanisms and diagnosis. In:Braunwald E, ed. Heart Disease. 7 th ed. Philadelphia: Sannders Company, 2005. 959-987.

共引文献52

同被引文献32

引证文献7

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部